Search Within

Richard Rifkind

Formats
  1. Journal Article (67)
  2. Meeting Abstract (40)
  3. Book Section (5)
  4. Conference Paper (5)
  5. Review (1)
Groups
  1. Department of Medicine (15)
  2. Center for Hematologic Malignancies (14)
  3. Solid Tumor Oncology Division (12)
  4. Surgery (12)
  5. Genitourinary Oncology Service (10)
  6. Pediatric Leukemia (6)

More Groups

People
  1. Paul Marks (113)
  2. Victoria Richon (76)
  3. Lang Ngo (14)
  4. Hiroaki Kiyokawa (12)
  5. Joseph Michaeli (11)
  6. Xianbo Zhou (11)

More People

Years
  1. 2007 (1)
  2. 2004 (2)
  3. 2003 (3)
  4. 2002 (8)
  5. 2001 (11)
  6. 2000 (11)

More Years

Publications
  1. Proceedings of the National Academy of Sciences of the United States of America (20)
  2. Proceedings of the American Association for Cancer Research Annual Meeting (19)
  3. Cancer Research (11)
  4. Blood (7)
  5. Clinical Cancer Research (7)
  6. Anticancer Research (5)

More Publications

Publishers
  1. American Association for Cancer Research (40)
  2. National Academy of Sciences (20)
  3. American Society of Hematology (7)
  4. International Institute of Anticancer Research (5)
  5. John Wiley & Sons (5)
  6. Elsevier Inc. (4)

More Publishers

Results (118)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation
    Journal Article

    Marrocco, D. L.; Tilley, W. D.; Bianco-Miotto, T.; Evdokiou, A.; Scher, H. I.; Rifkind, R. A.; Marks, P. A.; Richon, V. M.; Butler, L. M.
    Molecular Cancer Therapeutics (2007)

    Fulltext@MSK | Save
  • Induction of mitotic defect is a novel anti-tumor mechanism of histone deacetylase inhibitor suberoylanilide hydroxamic acid
    Meeting Abstract

    Xu, W.; Perez, G.; Gui, C.; Thapi, D.; Ngo, L.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.
    Cancer Research (2004)

    Fulltext@MSK | Save
  • Histone deacetylase inhibitor activation of p21 involves changes in promoter associated proteins, including HDAC1
    Meeting Abstract

    Gui, C.; Ngo, L.; Xu, W.; Thapi, D.; Perez, G. V.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.
    Cancer Research (2004)

    Fulltext@MSK | Save
  • Phase I clinical trial of an oral histone deacetylase inhibitor: Suberoylanilide hydroxamic acid (SAHA)
    Meeting Abstract

    Kelly, W. K.; O'connor, O.; Richon, V. M.; Curley, T.; Richardson, S.; Thapi, D.; Chiao, J. H.; Rifkind, R. A.; Marks, P. A.; Scher, H. I.
    Clinical Cancer Research (2003)

    Fulltext@MSK | Save
  • Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro
    Journal Article

    Kutko, M. C.; Glick, R. D.; Butler, L. M.; Coffey, D. C.; Rifkind, R. A.; Marks, P. A.; Richon, V. M.; LaQuaglia, M. P.
    Clinical Cancer Research (2003)

    Fulltext@MSK | Save
  • Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously
    Journal Article

    Kelly, Wm K.; Richon, V. M.; O'connor, O.; Curley, T.; Macgregor-Cortelli, B.; Tong, W.; Klang, M.; Schwartz, L.; Richardson, S.; Rosa, E.; more...
    Clinical Cancer Research (2003)

    Fulltext@MSK | Save
  • Differentiation and the role of differentiation inducers in cancer treatment
    Book Section

    Rifkind, R.; Richon, V.; Marks, P. A.; Breslow, R.
    In Bertino, J. R. (Eds.) Encyclopedia of Cancer. 2nd ed (2002)

    Fulltext@MSK | Save
  • Cloning and characterizing of HDAC9 and its alternatively spliced isoforms
    Meeting Abstract

    Zhou, X.; Marks, P. A.; Rifkind, R. A.; Richon, V. M.
    Proceedings of the American Association for Cancer Research Annual Meeting (2002)

    Fulltext@MSK | Save
  • The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) induces thioredoxin-binding protein-2 which blocks thioredoxin function
    Meeting Abstract

    Butler, L. M.; Zhou, X.; Scher, H. I.; Rifkind, R. A.; Marks, P. A.; Richon, V. M.
    Proceedings of the American Association for Cancer Research Annual Meeting (2002)

    Fulltext@MSK | Save
  • Histone deacetylase inhibitors and the treatment of cancers
    Meeting Abstract

    Rifkind, R. A.; Richon, V.; Breslow, R.; Marks, P. A.
    Abstracts of Papers of the American Chemical Society (2002)

    Fulltext@MSK | Save